AURA vs NVS vs REGN vs PFE vs JPM

For growth investors, Novartis AG (NVS) is the stronger pick with 6.

0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Aura Biosciences, Inc. (AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus Novartis AG at 21. 3x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Regeneron Pharmaceuticals, Inc. 's 2. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -56. 7% for Aura Biosciences, Inc. (AURA). Over 10 years, the gap is even starker: JPM returned +465. 8% versus AURA's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 38β versus Aura Biosciences, Inc. 's 1. 68β — meaning AURA is approximately 345% more volatile than PFE relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novartis AG (NVS) is pulling ahead at 6.

0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 0. 0% for Aura Biosciences, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 0. 0% for AURA. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Regeneron Pharmaceuticals, Inc. 's 2. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 17. 5x for Novartis AG — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AURA: 165. 2% to $17. 00.

In this comparison, PFE (6.

6% yield), NVS (2. 6% yield), JPM (1. 9% yield), REGN (0. 6% yield) pay a dividend. AURA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 2. 6% yield, +187. 2% 10Y return). Aura Biosciences, Inc. (AURA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +187. 2%, AURA: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AURA (Healthcare) and NVS (Healthcare) and REGN (Healthcare) and PFE (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AURA is a small-cap quality compounder stock; NVS is a large-cap quality compounder stock; REGN is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock; JPM is a large-cap deep-value stock. NVS, REGN, PFE, JPM pay a dividend while AURA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.